News On Novavax Vaccine

Novavax sees weak Covid vaccine sales

Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales

(Reuters) -Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi. Shares of the U.S. biotech firm fell 3% to $8.73.

The Business Journals · 22h

Novavax sees weak Covid vaccine sales, convinced Sanofi can do better

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals and a pipeline of new vaccines it's now evaluating for R&D.

Yahoo Finance · 1d

FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its Covid-19 and influenza combination vaccine (CIC) and standalone influenza vaccines after a month-long clinical hold. The FDA initially ...

MarketWatch · 2d

Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.

Hosted on MSN1d

Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again

Novavax (NVAX) shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its ...

Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

Business Insider1h

Novavax price target lowered to $9 from $14 at TD Cowen

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

AOL1d

Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals

Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, ...

KSL1d

FDA lifts clinical hold on Novavax's combo COVID-flu shot

The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...

Business Insider13h

Novavax Advances Vaccine Strategy Amid Financial Shifts

In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...

FiercePharma7d

Novavax coughs up $123.8M to settle COVID vaccine supply dispute with UK

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

Novavax, UK terminate vaccine supply agreement

Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...

Hosted on MSN3d

Should Kids Get the COVID-19 Vaccine?

They may be eligible for Novavax, which is a different COVID vaccine. Novavax is approved for children aged 12 and ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results